Aplicación YC de Cofactor Genomics

Summer 2015Active

Cofactor Genomics pasó por Y Combinator en el batch Summer 2015 como una empresa de Healthcare. Abajo: qué hace la empresa, quién la fundó y su aplicación a YC, reconstruida pregunta por pregunta en el formulario real de YC.

Batch YC: Summer 2015
Industria: HealthcareDiagnostics
Tamaño del equipo: 13
Estado: Active
Lanzado: 2015

Fundadores

Dave MessinaFounder/COO
Jarret GlasscockFounder/CTO

Lo que hace Cofactor Genomics

Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).

Aplicación YC de Cofactor Genomics, reconstruida

Solicitud de Y Combinator

Cofactor Genomics, batch Summer 2015. Las preguntas reales del formulario, respondidas con datos públicos.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Cofactor Genomics

Describe what your company does in 50 characters or less.

Cofactor closes the precision medicine gap with predictive diagnostics

What is your company going to make? Please describe your product and what it does or will do.

We build diagnostic tests using RNA sequencing and predictive immune modeling to create biomarkers that better predict patient responses, mainly for cancer immunotherapy. Our product helps doctors select which patients will respond to specific treatments, improving outcomes where current diagnostics fall short.

Where do you live now, and where would the company be based after YC?

We live and work in St. Louis, Missouri, and the company remains based there.

Explain your decision regarding location.

St. Louis grounds us with access to strong genomics talent and a supportive healthcare ecosystem, including relationships with national healthcare systems. We don't see a need to relocate right now.

21 respuestas más en la aplicación completa

están en la versión completa. Crea una cuenta gratuita para abrirla en YC Insights, junto a cada otro batch de YC.

Ver aplicación completa

Preguntas Frecuentes

¿Es esta la aplicación YC real de Cofactor Genomics?

No. Y Combinator mantiene privadas las aplicaciones enviadas. Esta es una reconstrucción: las preguntas reales del formulario de YC, respondidas a partir de los datos públicos de Cofactor Genomics (notas de lanzamiento, antecedentes de fundadores, descripción del producto). Muestra cómo una empresa como Cofactor Genomics se presentaría a YC, no el texto que enviaron.

¿En qué batch de YC estuvo Cofactor Genomics?

Cofactor Genomics formó parte del batch Summer 2015 de Y Combinator.

¿Quién fundó Cofactor Genomics?

Cofactor Genomics fue fundado por Dave Messina, Jarret Glasscock.

¿A qué se dedica Cofactor Genomics?

Cofactor closes the precision medicine gap with predictive diagnostics

¿Cómo leo la aplicación completa reconstruida?

Crea una cuenta gratuita de Round Funded. La versión completa de 26 respuestas de la aplicación de Cofactor Genomics, y de cada otro batch de YC, está en YC Insights.